Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

Fig. 4

ROC analysis of plasma Aβ oligomer levels measured using the MDS. a ROC analysis showed that plasma Aβ oligomer levels measured using MDS could discriminate between the AD and NC groups with an AUC of 0.844. The best sensitivity and specificity were 78.3% and 86.5%, respectively. b The AUCs for the biomarkers were as follows: PIB SUVR (AUC 0.9707, 95% CI 0.9309–1.000), CSF tTau/Aβ42 ratio (AUC 0.9689, 95% CI 0.9285–1.000), and CSF pTau/Aβ42 ratio (AUC 0.9542, 95% CI 0.8916–1.000). The AUC for plasma Aβ oligomer levels had the lowest value (AUC 0.8645, 95% CI 0.7535–0.9754) among those of other biomarkers of Alzheimer’s disease, although the difference was not statistically significant (p = 0.2503). Sn Sensitivity, Sp Specificity, MDS RLU Multimer Detection System relative luminescence units, PIB SUVR 11C-Pittsburgh compound B standardized uptake value ratio, CSF Aβ 42 Cerebrospinal fluid amyloid-β 1–42, CSF tTau/Aβ 42 Cerebrospinal fluid total tau protein/Aβ42 ratio, CSF pTau/Aβ 42 Cerebrospinal fluid phosphorylated tau protein/Aβ42 ratio

Back to article page